Apollo Hospitals Enterprise Ltd Share Price – NSE  / BSE

Healthcare, Mid Cap

04 Dec 2024 | 03:59 PM

7,234.45
108.05 (1.52%)

Independent Research

Reuters

We bring you Independent research views from famous names like Reuters and theScreeners to help improve your investing results and create wealth

Performance parameters

  • Earnings Revision Trend

    Analysts negative since 27-Mar-2020

    Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 27-Mar-2020 at a price of 1167.00.

  • Valuation Rating

    Strongly undervalued

    Based on its growth potential and our own criteria, at its current price the stock is strongly undervalued.

  • MT Tech Trend

    Trend neutral but previously positive (since 28-Apr-2020)

    The stock is currently trading close to its forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this (since 28-Apr-2020), the stock traded above its moving average. The confirmed Technical Reverse point (Tech Reverse - 1.75%) is 1374.969.

  • 4W REL Performance

    vs. SENSEX30

    The four week relative overperformance versus SENSEX30 is 8.770.

Risk parameters

  • Risk Zone

    Low

    The stock has been on the low-sensitivity level since 07-Feb-2020.

  • Bear Market

    Below average sensitivity to market corrections

    On average, the stock has a tendency to minimize the drops in the index by -103%.

  • Bad News

    Slight market sanction in case of specific pressure

    When the stock's pressure is specific, the market sanction on average is 258%.

  • Beta

    55 Low sensitivity to SENSEX30

    For 1% of index variation, the stock varies on average by 55%.

  • Correlation

    0.45 Fair correlation to SENSEX30

    0.4539% of stock movements are explained by index variations.

  • Value at Risk

    Rs.147.01 The medium term value at risk is estimated at 147.01 or 0.10543%

    The value at risk is estimated at 147.01. The risk is therefore 0.10543%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.

Other parameters

  • LT Growth

    37.27 Current year to 2022 annualized estimate

    The annualized growth estimate is for the current year to 2022.

  • P/E Ratio

    31.34 Estimated PE for 2022

    The estimated PE is for the year 2022.

  • G/PE Ratio

    1.21 25.408% discount to expected growth

    A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of 25.408%.

  • Dividend Yield

    0.55% Dividend is largely covered by profits

    The twelve month estimated dividend yield represents 17.239% of earnings forecasts.

  • Global Evaluation

    Positive

    The stock is classified in the positive zone since 28-Apr-2020.